December 2014 Blog Posts (2)

Supplemental Biologics License Application for Obinutuzumab Approved for Previously Untreated Chronic Lymphocytic Leukemia

The U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application or sBLA for obinutuzumab (Gazyva®; Genentech/Roche) in combination with chlorambucil chemotherapy in people with previously untreated chronic lymphocytic leukemia (CLL). The sBLA adds to the label data from Stage 2 of the CLL11 study showing significant improvements with Gazyva plus chlorambucil across multiple clinical endpoints when compared head-to-head with rituximab; Rituxan®;…

Continue

Added by Editorial Team on December 24, 2014 at 1:00pm — No Comments

Majority Elderly Women with Early Stage Breast Cancer may Not Benefit from the Treatment They Receive

Data from a new analysis published early online in Cancer, a peer-reviewed journal of the American Cancer Society has found that while clinical trial data support omitting radiation treatments in elderly women with early stage breast cancer, nearly two-thirds of these women continue to receive it.

Results published in 2004 from a large, randomized clinical trial showed that adding radiation therapy to surgery plus tamoxifen does not reduce 5-year recurrence rates or prolong…

Continue

Added by Editorial Team on December 8, 2014 at 3:30am — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+